MetLife Investment Management’s ADC Therapeutics ADCT Stock Holding History

MetLife Investment Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-53,690	Closed	-$201K	–	2885
2026 Q1	$201K	Buy	53,690 +4,008	+8%	+$15.8K	﹤0.01%	2224
2025 Q4	$175K	Buy	49,682 +19,633	+65%	+$79.7K	﹤0.01%	2335
2025 Q3	$120K	Sell	30,049 -14,978	-33%	-$47.2K	﹤0.01%	2573
2025 Q2	$121K	Sell	45,027 -460	-1%	-$968	﹤0.01%	2449
2025 Q1	$64.1K	Buy	45,487 +14,370	+46%	+$24.4K	﹤0.01%	2663
2024 Q4	$61.9K	Sell	31,117 -11,972	-28%	-$31.3K	﹤0.01%	2721
2024 Q3	$136K	Buy	43,089 +24,279	+129%	+$76.6K	﹤0.01%	2486
2024 Q2	$59.4K	Buy	+18,810	New	+$74.8K	﹤0.01%	2732

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MetLife Investment Management's ADCT Position: Q2 2026 in Review

MetLife Investment Management sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 53,690 shares — an estimated $201K sold.

MetLife Investment Management first reported a position in ADCT in Q2 2024 and held it in 8 quarters. The position peaked at $201K in Q1 2026. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

MetLife Investment Management reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
MetLife Investment Management sold 53,690 ADC Therapeutics shares in Q2 2026, an estimated $201K.
MetLife Investment Management first reported a position in ADC Therapeutics in Q2 2024 and held it in 8 quarters.
MetLife Investment Management's ADC Therapeutics position peaked at $201K in Q1 2026.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.